A recombinant anti-EGFR human/murine chimeric IgG1 monoclonal antibody (cetuximab biosimilar candidate) given as a single IV dose; binds EGFR (ErbB1/HER1), blocks EGF/TGF-α binding and receptor activation, promotes receptor internalization, inhibits RAS–RAF–MEK–ERK and PI3K–AKT signaling, and can mediate ADCC via its IgG1 Fc.
Chimeric IgG1 monoclonal antibody targeting EGFR (ErbB1/HER1); competitively blocks EGF/TGF-α binding, prevents receptor activation and promotes internalization, thereby inhibiting downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling to suppress tumor cell proliferation and survival; Fc region can engage Fcγ receptors to mediate ADCC.
YES
DIRECT
IgG1 Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC against EGFR-expressing cells; may also trigger complement-dependent lysis, while EGFR blockade is mainly antiproliferative.
A recombinant anti-EGFR human/murine chimeric IgG1 monoclonal antibody (cetuximab biosimilar candidate) given as a single IV dose; binds EGFR (ErbB1/HER1), blocks EGF/TGF-α binding and receptor activation, promotes receptor internalization, inhibits RAS–RAF–MEK–ERK and PI3K–AKT signaling, and can mediate ADCC via its IgG1 Fc.
Chimeric IgG1 monoclonal antibody targeting EGFR (ErbB1/HER1); competitively blocks EGF/TGF-α binding, prevents receptor activation and promotes internalization, thereby inhibiting downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling to suppress tumor cell proliferation and survival; Fc region can engage Fcγ receptors to mediate ADCC.
NO
INDIRECT
The antibody’s Fc binds CD16a on NK cells to activate ADCC against EGFR-expressing tumor cells; CD16a+ cells are effectors, not targets.
CAR T cells generated via lentiviral transduction to recognize CD133; IV dose-escalated infusion; targets CD133+ myeloid progenitors/blasts using CAR-mediated T-cell activation and cytotoxicity.
Autologous/allogeneic T cells are lentivirally engineered to express a chimeric antigen receptor targeting CD133. CAR engagement of CD133 on myeloid progenitors/blasts triggers MHC-independent T-cell activation, leading to perforin/granzyme-mediated cytotoxicity and cytokine-driven tumor cell clearance.
YES
DIRECT
CD133-directed CAR T cells engage CD133 on target cells, triggering MHC-independent T-cell activation and perforin/granzyme-mediated cytolysis, with additional cytokine-driven killing.
Reference product (Erbitux); a recombinant chimeric anti-EGFR IgG1 monoclonal antibody that binds EGFR, blocks ligand binding and receptor activation, induces receptor internalization, inhibits downstream signaling (RAS–RAF–MEK–ERK, PI3K–AKT), and mediates ADCC.
Cetuximab is a chimeric IgG1 monoclonal antibody against EGFR (ErbB1/HER1). It binds the extracellular domain of EGFR, blocks ligand (EGF/TGF-alpha) binding, prevents receptor activation and dimerization, promotes receptor internalization, and inhibits downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling, reducing proliferation and survival of EGFR-expressing tumor cells; its IgG1 Fc can also mediate ADCC.
YES
DIRECT
Cetuximab binds EGFR on target cells and engages Fcγ receptor–bearing effectors (e.g., NK cells) to mediate ADCC, with possible CDC; signaling blockade is largely cytostatic.
Reference product (Erbitux); a recombinant chimeric anti-EGFR IgG1 monoclonal antibody that binds EGFR, blocks ligand binding and receptor activation, induces receptor internalization, inhibits downstream signaling (RAS–RAF–MEK–ERK, PI3K–AKT), and mediates ADCC.
Cetuximab is a chimeric IgG1 monoclonal antibody against EGFR (ErbB1/HER1). It binds the extracellular domain of EGFR, blocks ligand (EGF/TGF-alpha) binding, prevents receptor activation and dimerization, promotes receptor internalization, and inhibits downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling, reducing proliferation and survival of EGFR-expressing tumor cells; its IgG1 Fc can also mediate ADCC.
NO
INDIRECT
Cetuximab binds EGFR on tumor cells; its IgG1 Fc engages FcγRIIIa (CD16A) on NK cells to trigger ADCC, killing EGFR-positive cells. CD16A-expressing cells are effectors, not killed.